1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

Another Early-Stage VC Win: Pliant Raises $45m For Fibrosis Startup

 
• By Mandy Jackson

As venture capital investment in biotechnology skyrockets, the amount of money that companies can raise in first-time financings also is soaring to new heights, and the fibrosis-focused startup Pliant Therapeutics Inc. with its $45m Series A round is no exception to the new biotech VC rule.

As venture capital investment in biotechnology skyrockets, the amount of money that companies can raise in first-time financings also is soaring to new heights, and the fibrosis-focused startup Pliant Therapeutics Inc. with its $45m Series A round is no exception to the new biotech VC rule.

The surge in venture capital for early-stage drug development, which was driven in large part by generalist investors seeking high...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Rhythm Gets US Decision Date For Hypothalamic Obesity Treatment

 
• By Andrew McConaghie

Already approved in two rare obesity conditions, Rhythm’s Imcivree looks on course to gain acquired hypothalamic obesity approval and reach blockbuster status.

Madrigal Regains Lead With Rezdiffra MASH Approval In EU

 
• By Joseph Haas

Four days after Wegovy became the second approved MASH therapy in the US, Rezdiffra gets the first European approval. Plans are for an initial launch in Germany.

China-Originated Assets Lead Global GLP-1 Deals

 
• By Xu Hu

The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.

Discontinuations For Viking’s Oral Obesity Drug VK2735 Scare Investors

 
• By Joseph Haas

Analysts lauded the 13-week weight-reduction rates Viking’s oral dual GLP-1/GIP agonist showed in Phase II, but the firm’s stock tumbled 42% due to high discontinuation rates.

More from Therapy Areas

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By Kevin Grogan

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

BioNTech/BMS Bispecific Shows Early Promise In Small Cell Lung Cancer

 
• By Andrew McConaghie

An updated abstract from the World Conference on Lung Cancer has given analysts confidence in BioNTech’s VEGF-A/PD-L1 bispecific challenger

China-Originated Assets Lead Global GLP-1 Deals

 
• By Xu Hu

The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.